drugset / Trial / NCT00796107

A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer

NCT00796107

Phase 2 Terminated 6 enrolled Hoffmann-La Roche
NaSingle-groupOpen-labelTreatment

Summary

This study aim was to determine the safety and efficacy of R1507 in combination with letrozole in patients with advanced breast cancer. In the first part of the study a cohort of patients with advanced breast cancer received letrozole 2.5mg po daily in combination with R1507 16mg/kg every 3 weeks.

Timeline

Start
2009-01-28
Primary completion
2010-03-03
Completion
2010-03-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Letrozole Other / unclassified 2.5 mg Oral
Subject Teprotumumab Monoclonal antibody 16 mg/kg Intravenous

Indications